Short-term blinatumomab for B-cell acute lymphoblastic leukemia pediatric patients results in measurable residual disease clearance
Annals of Hematology · 06.05.2026 · 105 (7)
DOI: 10.1007/s00277-026-07028-7 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Annals of Hematology, online erschienen am 06.05.2026. Verfasst von Changwen Xue und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, National Clin…. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China, CAMS Innovation Fund for Medical Sciences, National Natural Science Foundation of China.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, National Clinical Research Center for Blood Diseases, Chinese Academy of Medical Sc…
- Tianjin Institutes of Health Science, Tianjin, 301600, China.
- Tianjin Institutes of Health Science, Tianjin, 301600, China. zhangli1@ihcams.ac.cn.
Förderung
- National Key Research and Development Program of China
- CAMS Innovation Fund for Medical Sciences
- National Natural Science Foundation of China
- Haihe Laboratory of Cell Ecosystem Innovation Fund
Zitieren
APA
Xue, C., Wu, C., Zhang, Y., Yang, W., Zou, Y., Guo, Y., Ma, Y., Chen, Y., Chen, X., Zhu, X., & Zhang, L. (2026). Short-term blinatumomab for B-cell acute lymphoblastic leukemia pediatric patients results in measurable residual disease clearance. Annals of Hematology, 105(7). https://doi.org/10.1007/s00277-026-07028-7
Vancouver
Xue C, Wu C, Zhang Y, Yang W, Zou Y, Guo Y, et al. Short-term blinatumomab for B-cell acute lymphoblastic leukemia pediatric patients results in measurable residual disease clearance. Annals of Hematology. 2026;105(7). doi:10.1007/s00277-026-07028-7
BibTeX
@article{Xue2026,
author = {Xue, Changwen and Wu, Chao and Zhang, Yingjin and Yang, Wenyu and Zou, Yao and Guo, Ye and Ma, Yueshen and Chen, Yumei and Chen, Xiaojuan and Zhu, Xiaofan and Zhang, Li},
title = {Short-term blinatumomab for B-cell acute lymphoblastic leukemia pediatric patients results in measurable residual disease clearance},
journal = {Annals of Hematology},
year = {2026},
volume = {105},
number = {7},
doi = {10.1007/s00277-026-07028-7}
}
EUVIMED